Resilient Biotics specializes in developing advanced microbiome-based therapeutics aimed at combating complex respiratory infections, particularly in the livestock industry. The company operates in the animal health market, focusing on creating non-antibiotic solutions to reduce dependency on traditional antibiotics and promote a more sustainable food supply. Resilient Biotics leverages proprietary databases and analytics pipelines to drive its discovery engine for new microbiome products. The company generates revenue through the development and commercialization of these innovative therapeutics, which are designed to enhance the health and wellbeing of animals by utilizing healthy microorganisms to act as barriers against dangerous pathogens. Resilient Biotics serves clients in the livestock industry, particularly those dealing with bovine respiratory disease (BRD), one of the most severe and costly diseases in this sector. The company operates out of Research Triangle, North Carolina, and the San Francisco Bay Area, with active research collaborations to further its mission of eliminating disease, reducing antibiotic resistance, and contributing to the overall understanding of the microbiome's role in promoting host health.

Keywords: microbiome, therapeutics, respiratory infections, livestock, non-antibiotic, animal health, bovine respiratory disease, sustainable food supply, pathogen barrier, microbiome discovery.